{"entity":{"id":"foundation-medicine","kind":"company","name":"Foundation Medicine (Roche)","aka":[],"tldr":"Maker of the FDA-approved FoundationOne CDx genomic test used across dozens of drug labels.","summary":"Foundation Medicine, based in Boston and owned by Roche, makes FoundationOne CDx, the FDA-approved comprehensive genomic profiling test written into dozens of drug labels. Its products include FoundationOne CDx and Liquid CDx, FoundationOne Tracker for measurable residual disease and FoundationOne Heme, and with Flatiron Health it built the largest real-world clinico-genomic database, which OnCo carries as a collection. OnCo links it to comprehensive genomic profiling, liquid biopsy and digital twins, to cancer of unknown primary, and to bottlenecks on unvalidated biomarkers, data silos and weak real-world evidence, with ideas on a single calibrated tumour mutational burden and machine-readable genomic reports attached. Whether a test owned by a drug company can be trusted as a neutral companion diagnostic is the fair question. FoundationOne has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.foundationmedicine.com"}],"tags":[],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":[],"targets":[],"drugs":["foundationone-cdx"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Boston, MA","country":"US","companyType":"diagnostics","website":"https://www.foundationmedicine.com","investors":[],"funding":[]},"route":"/companies/foundation-medicine/","neighbours":{"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"drug":[{"id":"foundationone-cdx","kind":"drug","name":"FoundationOne CDx / Liquid CDx","route":"/drugs/foundationone-cdx/"}],"paper":[{"id":"paper-radovich-ctdna-ctc-bre12-158-jama-oncol-2020","kind":"paper","name":"Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial","route":"/key-papers/paper-radovich-ctdna-ctc-bre12-158-jama-oncol-2020/"},{"id":"paper-javle-biliary-ngs-cancer-2016","kind":"paper","name":"Biliary cancer: utility of next-generation sequencing for clinical management","route":"/key-papers/paper-javle-biliary-ngs-cancer-2016/"},{"id":"paper-chung-comprehensive-genomic-profiling-prostate-jco-po-2019","kind":"paper","name":"Prospective comprehensive genomic profiling of 3,476 primary and metastatic prostate tumours","route":"/key-papers/paper-chung-comprehensive-genomic-profiling-prostate-jco-po-2019/"}],"idea":[{"id":"idea-moon-federated-rwe-network","kind":"idea","name":"A global federated real-world evidence network at regulatory grade","route":"/ideas/idea-moon-federated-rwe-network/"},{"id":"idea-tr2-tmb-calibration-standard","kind":"idea","name":"A single calibrated tumour mutational burden across all sequencing panels","route":"/ideas/idea-tr2-tmb-calibration-standard/"},{"id":"idea-tr1-drop-non-essential-biopsies","kind":"idea","name":"Drop mandatory fresh biopsies where blood or archival tissue would do","route":"/ideas/idea-tr1-drop-non-essential-biopsies/"},{"id":"idea-tr2-rwe-combination-emulation","kind":"idea","name":"Emulate combination trials from real-world data to triage which ones to run","route":"/ideas/idea-tr2-rwe-combination-emulation/"},{"id":"idea-data-structured-genomic-reports","kind":"idea","name":"Every tumour genomic report machine-readable and deposited nationally","route":"/ideas/idea-data-structured-genomic-reports/"},{"id":"idea-tr1-ngs-report-live-trial-match","kind":"idea","name":"Every tumour sequencing report lists open, nearby, matched trials pulled live","route":"/ideas/idea-tr1-ngs-report-live-trial-match/"},{"id":"idea-bio1-truncal-branch-labelling","kind":"idea","name":"Label every targetable mutation as truncal or branch on the report","route":"/ideas/idea-bio1-truncal-branch-labelling/"},{"id":"idea-bio1-open-resistance-atlas","kind":"idea","name":"One open atlas of how tumours escape every drug","route":"/ideas/idea-bio1-open-resistance-atlas/"},{"id":"idea-tr2-cdx-mutual-recognition","kind":"idea","name":"Regulators recognise each other's companion diagnostic approvals","route":"/ideas/idea-tr2-cdx-mutual-recognition/"},{"id":"idea-prostate-hrr-testing-at-metastatic-diagnosis","kind":"idea","name":"Test every man for DNA repair faults on the day his prostate cancer is found to have spread, not three treatments later","route":"/ideas/idea-prostate-hrr-testing-at-metastatic-diagnosis/"}],"technology":[{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"},{"id":"digital-twins-trials","kind":"technology","name":"Digital twins and virtual control arms","route":"/technologies/digital-twins-trials/"},{"id":"hrd-genomic-scar-scores","kind":"technology","name":"HRD genomic scar scores (GIS, LOH, HRDetect)","route":"/technologies/hrd-genomic-scar-scores/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"}],"bottleneck":[{"id":"b-biomarker-validation","kind":"bottleneck","name":"Biomarkers are not validated or standardised","route":"/bottlenecks/b-biomarker-validation/"},{"id":"b-data-silos","kind":"bottleneck","name":"Data silos","route":"/bottlenecks/b-data-silos/"},{"id":"b-care-fragmentation","kind":"bottleneck","name":"Fragmented care and guideline gaps","route":"/bottlenecks/b-care-fragmentation/"},{"id":"b-immunotherapy-response","kind":"bottleneck","name":"No one can predict who responds to immunotherapy","route":"/bottlenecks/b-immunotherapy-response/"},{"id":"b-real-world-evidence","kind":"bottleneck","name":"Weak real-world evidence and registries","route":"/bottlenecks/b-real-world-evidence/"}],"company":[{"id":"flatiron-health","kind":"company","name":"Flatiron Health (Roche)","route":"/companies/flatiron-health/"}],"cancer":[{"id":"cancer-of-unknown-primary","kind":"cancer","name":"Cancer of unknown primary (CUP)","route":"/cancers/cancer-of-unknown-primary/"}],"collection":[{"id":"flatiron-foundation-cgdb","kind":"collection","name":"Flatiron Health and Foundation Medicine Clinico-Genomic Database","route":"/collections/flatiron-foundation-cgdb/"}],"roadmap":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/"}],"trial":[{"id":"cupisco","kind":"trial","name":"CUPISCO","route":"/trials/cupisco/"},{"id":"i-predict","kind":"trial","name":"I-PREDICT","route":"/trials/i-predict/"},{"id":"lung-map","kind":"trial","name":"Lung-MAP (SWOG S1400 and S1900)","route":"/trials/lung-map/"},{"id":"winther","kind":"trial","name":"WINTHER","route":"/trials/winther/"}]}}